{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:44:13Z","timestamp":1790718253266,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New amyloid\u2010targeting monoclonal antibody (mAb) therapies for Alzheimer disease (AD) are currently under review by the Therapeutic Goods Administration for use in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To determine the infrastructure, workforce and training needs of Australian memory and cognition clinics in order to characterise health system preparedness for these therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A national, cross\u2010sectional online survey of medical specialists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty medical specialists (geriatricians,\n                      <jats:italic>n<\/jats:italic>\n                      =\u200923; psychiatrists,\n                      <jats:italic>n<\/jats:italic>\n                      =\u20094; neurologists,\n                      <jats:italic>n<\/jats:italic>\n                      =\u20093) from 30 different clinics participated (public, 76.7%; private, 23.3%), including from metropolitan (73.3%), regional (20.0%) and rural (6.7%) areas. On average, clinics reported assessing 5.4 (SD\u2009=\u20093.2) new patients per week, of which 2.4 (range: 0\u20135) were considered to have mild cognitive impairment (MCI). Only 40% of clinics use biomarkers to assess whether patients with MCI have AD, and 45% have intravenous infusion capability. While the majority of clinicians were confident in their knowledge of mAbs, only 33% felt confident in using these. Identified impediments to clinical implementation included (i) lack of real\u2010world experience,\u00a0(ii) lack of current Models of Care and appropriate use guidelines, (iii) current clinic set\u2010up and (iv) information about safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Australia's health system preparedness for amyloid\u2010targeting mAb therapies will require further investment in infrastructure, equity of access, clinician training and support. Long wait times already impact access to clinics, and with the forecast rise in MCI and dementia cases, services will need to be expanded, and appropriate Models of Care and clear and efficient inter\u2010sector health pathways will be needed to prepare for the use of mAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.16637","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:01:11Z","timestamp":1738818071000},"page":"1081-1089","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is Australia ready for the rollout of amyloid\u2010targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-8222","authenticated-orcid":false,"given":"Johannes C.","family":"Michaelian","sequence":"first","affiliation":[{"name":"Healthy Brain Ageing Program, Brain and Mind Centre and Charles Perkins Centre, School of Psychology, Faculty of Science University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging and Therapy, Austin Health The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Kurrle","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance Dimity","family":"Pond","sequence":"additional","affiliation":[{"name":"Wicking Dementia Research and Education Centre University of Tasmania  Hobart Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Woodward","sequence":"additional","affiliation":[{"name":"Department of Continuing Care, Austin Health The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Naismith","sequence":"additional","affiliation":[{"name":"Healthy Brain Ageing Program, Brain and Mind Centre and Charles Perkins Centre, School of Psychology, Faculty of Science University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180766"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01858-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_7_6_1","unstructured":"Biogen.\u201cLEQEMBI\u00ae\u201d (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China. [cited 2024 Oct 16]. Available from URL:https:\/\/www.tga.gov.au\/news\/news\/tgas-decision-not-register-lecanemab-leqembi"},{"key":"e_1_2_7_7_1","unstructured":"Biogen.\u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20.2023."},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.2023.12548","article-title":"Alzheimer drug lecanemab gains traditional FDA approval","volume":"330","author":"Harris E","year":"2023","journal-title":"JAMA"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.159"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263195"},{"key":"e_1_2_7_11_1","unstructured":"Australian Dementia Network.Find a clinic or service[cited 2024 Jun 17]. Available from URL:https:\/\/www.australiandementianetwork.org.au\/initiatives\/clinical-quality-registry\/find-a-clinic-or-service\/"},{"key":"e_1_2_7_12_1","unstructured":"Qualtrics.Qualtrics. Provo Utah USA.2020."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220288"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038624"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03253-7"},{"key":"e_1_2_7_17_1","unstructured":"WardSA AhernS BrodatyH WallisK LinX TsuiA et al.The Australian Dementia Network (ADNeT) Registry First Annual Report (2020\u20102021). Monash University Department of Epidemiology and Preventive Medicine; 2022. Report No.: 1; 56."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230854"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12307"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12503"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T16:05:08Z","timestamp":1752077108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/imj.16637"],"URL":"https:\/\/doi.org\/10.1111\/imj.16637","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.05.24309974","asserted-by":"object"}]},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"2024-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}